Clinical Trials
-
Principal Investigator:
Nobuko Hijiya, MDThe purpose of this study is to determine if a study drug called pembrolizumab is safe and effective in the treatment of children and adolescents who have advanced melanoma, or advanced, relapsed, or refractory PD-L1 positive malignant solid tumor or other lymphoma, relapsed or refractory classical Hodgkin lymphoma (rrcHL), advanced, relapsed or refractory microsatellite-instability-high (MSI-H) solid tumor. Participants might be at least 6 months (3 years rrcHL) to less than 18 years old and able to provide the sample for testing the PD-L1 (programmed cell death ligand 1) purpose from an... -
Principal Investigator:
Nobuko Hijiya, MDThis Phase III trial investigates if the incorporation of immunotherapy will improve progression-free survival (PFS) and maintain overall survival (OS) while simultaneously minimizing long-term morbidity and treatment-related mortality by reducing exposure to radiotherapy and high cumulative chemotherapy doses. The study will enroll patients ages 5 to 60 years with newly diagnosed early-stage cHL and will investigate the targeted CD30-antibody drug conjugate, Brentuximab Vedotin (Bv), with PD-1 blockade (nivolumab) compared with a standard chemotherapy regimen, with or without radiotherapy. -
Principal Investigator:
Nobuko Hijiya, MDThis is a phase 1 study for participants with relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) diagnosis. This study will observe the safety, side effects, and best dose of Imetelstat as an investigational drug, or drug that is not approved by the Food and Drug Administration (FDA), that can improve a disease or condition. Participants will receive Imeletstat intravenously (IV), and undergo study procedures such as blood and cerebrospinal fluid sample collection, as well imaging scans. -
Principal Investigator:
Mercedes Martinez, MDThe purpose of this study is to better understand how common and how severe pruritis (itching) is in children and adults under 21 years of age with Primary Sclerosing Cholangitis (PSC). The study involves the completion of two short online surveys. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC). -
Principal Investigator:
Mercedes Martinez, MDThe purpose of this study is to better understand how common and how severe pruritis (itching) is in children and adults under 21 years of age with Primary Sclerosing Cholangitis (PSC). The study involves the completion of two short online surveys. If you have any questions regarding this study, please contact the Transplant Clinical Research Center ( TCRC). -
Principal Investigator:
Meyer Kattan, MDWe are interested in learning more about these diseases and how to treat them. Our research program is conducting several studies including: a study to learn if treatment with a drug named dupilumab can help reduce asthma attacks in children, a study to observe a specific type of irritation in the lungs and how it relates to asthma symptoms, and more! If you live in the city or surrounding counties and have an interest in participating in research studies, you may be eligible to join a registry of participants. Our research focuses on children, but all ages are eligible to join. Contribute to... -
Principal Investigator:
Meyer Kattan, MDWe are interested in learning more about these diseases and how to treat them. Our research program is conducting several studies including: a study to learn if treatment with a drug named dupilumab can help reduce asthma attacks in children, a study to observe a specific type of irritation in the lungs and how it relates to asthma symptoms, and more! If you live in the city or surrounding counties and have an interest in participating in research studies, you may be eligible to join a registry of participants. Our research focuses on children, but all ages are eligible to join. Contribute to... -
Principal Investigator:
Vidhu Thaker, MDWe will enroll children with severe early onset obesity (BMI 99th percentile) diagnosed prior to 6years of age or other endocrine disorders. We will ask questions about their health, eating behavior and perform a brief physical examination. We will collect saliva or blood to perform genetic testing. We will also invite family members to participate in the genetic study. -
Principal Investigator:
Ilene Fennoy, MDThis study is being done to learn more about how weight-loss surgery or a medicine called glucagon-like peptide-1 receptor agonist (GLP-1RA) affects the bacteria in your mouth and stool. We are also trying to understand how these changes might be connected to your liver health and cholesterol levels. This information could help doctors take better care of children who need these treatments in the future. -
Principal Investigator:
Usha S Krishnan, MDThis study is being done to determine whether early combination therapy with two study drugs called sildenafil (REVATIO) and bosentan (TRACLEER) can improve pulmonary hypertension when compared to using sildenafil alone. Pediatric pulmonary arterial hypertension (PAH) is a severe medical problem that often worsens with time. It is caused by problems with the growth and/or function of the arteries that supply blood to the lungs. This is a growing problem in the world today. Despite the serious nature of this disorder, the medical field does not yet know the best first treatment for infants,...